Biocon Ltd posted a nearly 20% year-on-year rise in consolidated revenue to ₹4,296 crore for the quarter ended September 2025 (Q2 FY26), fuelled by strong growth in its biosimilars business and continued international expansion.

According to the company’s filing, operating profit (EBITDA) rose over 40% YoY, supported by higher product volumes and cost efficiencies. The biosimilars segment — Biocon’s largest growth engine — benefited from expanded market access in the US and Europe as well as steady gains in emerging markets.

Chairperson Kiran Mazumdar-Shaw said the results reflected the “resilience of Biocon’s diversified business model” and reaffirmed the company’s focus on innovation-led, affordable healthcare. She added that R&D investments and pipeline progress would remain prioriti

See Full Page